Truist lowered the firm’s price target on Biote (BTMD) to $7 from $9 and keeps a Buy rating on the shares. The company’s Q4 was a challenging ...

Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of biote in a research note ...

and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. Receive News & Ratings for biote Daily - Enter your email address ...

BIOTE ($BTMD) posted quarterly earnings results on Wednesday, March 12th. The company reported earnings of $0.10 per share, missing estimates of $0.10 by $0.00. The ...

Reports Q4 revenue $49.8M, consensus $51.2M. “In 2024 Biote (BTMD) strengthened its capabilities to provide the next level of individualized and evidence-based healthcare,” said Bob Peterson ...

“In 2024 Biote strengthened its capabilities to provide the next level of individualized and evidence-based healthcare,” said Bob Peterson, Biote Chief Financial Officer. “Full year 2024 ...

Good day and welcome to the Biote fourth quarter 2024 earnings conference call. (Operator Instructions) Please note that this event is being recorded. I would now like to turn the conference over ...

Good day, and welcome to the Biote Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. I would now like to turn the conference ...